



Press Release

Publisher: University
Communication
Editor: Dr. Gabriele Neumann
Tel. 0049-6421 28-23010
Fax 0049-6421 28-28903
E-Mail: gabriele.neumann@uni-
marburg.de
Marburg, 12. July 2022

EU innovation radar includes SciFiMed project

Research project aims to develop a biosensor to diagnose and treat serious diseases

The European Commission has analyzed the SciFiMed project, a Horizon 2020 project led by Prof. Dr. Diana Pauly from the Department of Medicine at Philipps University Marburg, and included it as an excellent scientific project in the EU Innovation Radar.

The Innovation Radar is an initiative of the European Commission to identify innovations and innovators with high potential in EU-funded research and innovation projects. The aim is to enable all interested parties (citizens, professionals and business people, etc.) to discover the results of EU innovation funding and to locate innovators. Better access to this information should foster the development of a dynamic ecosystem of incubators, entrepreneurs, funding agencies and investors, which can help bring EU-funded innovations to market faster.

One of the goals of the SciFiMed project is to develop a biosensor that can be used directly at the bedside or in medical practices to diagnose and treat serious diseases. These are diseases associated with a deregulation of the immune system, for example degenerative eye diseases, chronic kidney disease or bacterial infections. These can be detected more quickly and treated more effectively with the help of the biosensor. Currently, around 190 therapeutic variants are being investigated in more than 870 clinical trials, all of which target the dysregulation of this immunological signaling pathway. More than 2 million people are participating in these trials, but rapid, cost-effective and comprehensive diagnostics of the pathological mechanisms are still lacking, making SciFiMed's groundbreaking new biosensor technology even more important and necessary.

SciFiMed

The three SciFiMed partners (University of Regensburg, Sanquin NL, Microcoat GmbH) are in charge of the development of the innovation "Point of care biosensor to improve diagnostics of diseases associated with a dysregulation of the immune system".

In total, the University of Regensburg, the Complutense University of Madrid, the Eötvös Loránd University in Budapest, the University Medical Center Groningen, the healthcare institution Sanquin (Netherlands) and the biotechnology companies Hycult Biotech (Netherlands) and Microcoat Biotechnologie GmbH (Germany) are involved in the research

project, which is coordinated by the Philipps University of Marburg. The international and interdisciplinary team is not only working to advance immunology research, but also aims to enable new treatment options and novel approaches to drug development. This project was funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 899163.

You can learn more about SciFiMed at www.scifimed.eu.

SciFiMed on the EU Innovation Radar: <https://www.innoradar.eu/innovation/45859>

More information:

Veronika Ehinger
Experimental Ophthalmology
Department of Medicine
Philipps University Marburg

Tel.: 06421 58-66251

E-mail: ehinger6@staff.uni-marburg.de